6 PROGRAM REGIONAL MEETING Message from the ISBER President and Scientific Program Committee Co-Chairs Dear colleagues and friends, This year the International Society of Biological and Environmental Repositories (ISBER) is celebrating an important milestone, its 20th anniversary. It represents more than just a passage of time and persistence, but also the culmination of two decades of creativity, innovation and growth. This anniversary provides an opportunity to reflect upon the cherished memories of years gone by while celebrating another year of serving our members, community, and successes.
As we continue our 20th year celebration after an incredible conference in Shanghai, China, the ISBER Board of Directors and the Co-Chairs of the 2019 Americas Regional Meeting welcome you to Minneapolis, MN and hope you have an enjoyable and interesting three days filled with thought provoking presentations, stimulating conversations and fun networking! The city is home to the largest health technology cluster in the United States, with over 350 medical device companies calling this area home. In honor of Bob Dylan, a native of Minnesota, the Scientific Program Advisory Committee chose "Times they are a changin': Biobanks for the Future" as this regional meeting theme. The theme of the conference, influenced by titles of Bob Dylan's extensive music catalog, are threaded throughout the meeting symposia.
In keeping with the theme, the regional program will focus on the evolving composition of biobanks and their progressive involvement in research. Biobanks now encompass much of the developing digital world and the regional meeting reflects this by focusing on digital biobanking and the collection of data for research from wearable technology. Biobanks have also expanded to developing living biobanks of cells, disease models, microbiomes and reprogrammed cells -each with complex challenges in maintaining these biobanks for future research. This changing face of biobanking is highlighted by the addendum to the fourth edition of the ISBER Best Practices. This addendum builds upon previous editions of the Best Practices of 2005, 2008, 2012, and 2018 and focuses on the liquid nitrogen (LN2)-based cryogenic storage of living biological and environmental specimens for research and clinical use.
PRECONFERENCE WORKSHOP
New to biobanking? This year, we are offering Biobanking 101 (additional registration required) as a preconference workshop held on Sunday, November 3rd which will introduce practical knowledge on the construction of consents, cold chain management, and harmonizing repository practice.
Participants will have the opportunity to learn about use of tools developed by ISBER to help set up and manage biobanks. Joanne Demchok (National Cancer Institute) will focus on one of ISBER's tools, the International Repository Locator. Information will be provided about various repository locators and how tools can be accessed and utilized.
Obtaining informed consent for the collection and use of biospecimens can be a tremendous challenge and will be the second topic covered. Helena Ellis (Biobanking Without Borders, LLC) will be will be conducting a session on "How to write a Biobanking Informed Consent Document". This workshop will provide easy to implement instructions to write clear biobanking consent forms based on best practices and will help participants understand both challenges and best practices for writing an informed consent document.
Quality and stability of a biospecimen requires proper cold chain management. This will be the third topic covered. Kathi Shea (Brooks Life Sciences) will discuss various methods, tools and best practices for cold chain management. Breakout discussions will help participants to address specific questions and network with other biobankers. 7 PROGRAM REGIONAL MEETING NOVEMBER 3-5
PROGRAM HIGHLIGHTS
The three day program includes roundtable discussions, a welcome reception, eight symposia sessions, two contributed paper sessions, four educational workshops, a networking reception, and numerous opportunities to network and learn more from our corporate sponsors at workshops and the exhibit hall booths.
The first full day of the program, Monday, is kicked off by an opening address by Debra Garcia, 2019-2020 ISBER President, followed by the keynote speaker Abasi Ene-Obong, CEO and founder of 54gene, who will provide perspective on building a pan-African biobank to promote genomic diversity in population health research. Monday will end with a networking event for all attendees.
Tuesday opens with Symposium 5: Forever Young? Biospecimen Quality to Ensure Longevity, followed by the contributed paper sessions and a sponsored lunch symposium. The day concludes with concurrent sessions Symposium 6A: Shelter from the Storm: Keeping Biospecimens Alive and Symposium 6B: Integrating Digital Biospecimens: Don't Leave Them "Blowin' in the Wind" and the closing ceremony.
Four educational workshops will also be offered on Tuesday, November 5th: Consent for Future Use of Biospecimens Under the Revised Common Rule; Pitching Biobanking; If it's Fitness-for-Purpose You're Chasing…The Tools, They are a Changin: Leveraging Standards, ISBER Tools and Other Resources; Irreproducible Research Based on Human Biospecimens: Can New Models of Bioresources Ameliorate This Problem? Please join us for this important opportunity to learn with your colleagues as we reflect on modern and future repository challenges in the closing months of ISBER's 20th anniversary.
SOCIAL EVENTS
The conference is set in downtown Minneapolis. The Stone Arch Bridge is a short walk away from the conference venue with a spectacular view of the Mississippi River and the Saint Anthony Falls. The sunsets on the bridge are spectacular. Minneapolis is also home to a large number of breweries and distilleries combined with a vibrant restaurant scene. If you choose to pursue your musical interests, a visit to Paisley Park, Prince's private estate and music production complex is warranted.
ACKNOWLEDGEMENTS
We would like to thank our invited speakers and workshop presenters for their generous contributions to the program. Additional thanks are due to the many ISBER volunteers whose hands-on involvement in the planning and implementation process made the program possible. Members of the ISBER 2019 Regional Meeting and Scientific Program Committee, as well as the Organizing Advisory Committee (OAC), contributed a tremendous amount of time and effort in the last year, resulting in the wonderful program we will soon experience. Additional assistance was provided by the Education and Training Committee who worked so hard to organize the pre-conference and educational workshops.
We would also like to give a special acknowledgement to Marianne Henderson for her tremendous support and guidance to this year's program committee. Marianne will be stepping down as the OAC's Chairperson after 6.5 years of service.
We greatly appreciate the support received from our vendors and sponsors, whose participation also made the meeting possible. Please visit the exhibition hall to support the vendors and check out the corporate workshops throughout the meeting schedule.
Finally, we would like to thank the ISBER Heard Office staff under the direction of Ana Torres for their continual support and guidance.
Your feedback is very important to ISBER. The regional meeting is developed and produced by volunteer membership and the success of future meetings relies on your participation and input. As a reminder, please complete the electronic survey at the end of the meeting. Monday, November 4 9:30am -8:00pm
ISBER WORKING GROUPS
Tuesday, November 5 9:00am -3:45pm
CERTIFICATES OF ATTENDANCE
All attendees will receive a certificate of attendance after completion of the post-conference evaluation. The evaluation will be distributed via email following the meeting.
WI-FI

Network:
Renaissance_CONFERENCE Conference Code: Anaheim2020
POSTER PRESENTATION INFORMATION:
Poster Set-Up: Sunday, November 3 6:00pm -6:30pm
Poster Tear-Down: Tuesday, November 5 3:15pm -3:45pm REGISTRATION RATES (PRICES IN USD) All delegates are encouraged to register for the meeting prior to arriving on-site, though on-site registrations will be accepted. Exhibit hall pass includes access to the exhibit hall, conference meals served in the exhibit hall, and access to all networking events.
Regular
NETWORKING EVENTS
All delegates are invited and encouraged to attend the two networking receptions: 12 PROGRAM REGIONAL MEETING Prevention and precision medicine for all relies on biobanks and research studies that include specimens from diverse populations to answer questions that are generalizable and specific for certain populations. Inclusion of diverse, underserved and specialized populations in research requires special attention to governance structures and active approaches to community engagement. Attention to privacy and trust relationships is a significant element of success. This symposium will discuss the opportunities and challenges in precision medicine and prevention for all, community engagement, IRB governance with a highlight on the activities of All of Us Cohort and other large studies that impact communities. The digital health industry has sprung up quickly in recent years. Easy access to direct to consumer genetics for ancestry and health risk analysis, personal digital health trackers to monitor constantly vital statistics, and lifestyle have contributed significantly to this growth. In 2018, it was predicted that venture capitalists and health systems would invest in the region of $7 billion in digital health solutions including wearables and biosensors like Fitbits, precision medicine and genomics, mobile diagnostics, and clinical decision support via telemedicine. Whilst the FDA regulates medical devices, it does not regulate all genetic services or wearable devices. Wearable data tracking and direct to consumer genetics data have many elements in common. They enable the individual to produce vast amounts of health-related data that are an incredible source of data for research and public health, they raise privacy concerns, and they open a market for individual selling of personal data. In this session, we will discuss the implications of such bio-voyeurism, whether (and how) such data should be shared and banked for future research use and the challenges to be overcome to facilitate such sharing. We will address potential policy gaps and self-regulation recommendations required to ameliorate privacy concerns and other ethics and governance issues related to big data banking. Sustainability is a complex and ongoing challenge for most biobanks around the world. A biobank's mission, sample types, numbers and types of stakeholders served and source(s) of funding, impacts the importance of sustainability in a biobank's business plan. Furthermore, sustainability issues encompass all financial, social and operations aspects of a biobank. This session will be an interactive moderated discussion with representatives of four different Minnesota biobanks across biobanking sectors, including human, non-human and environmental samples that have achieved sustainability. Each speaker will clearly describe their biobank's mission, essential elements, sample and stakeholder statistics and operating principles. The moderator will engage with all speakers in a 'talk show style' to elicit information of how they define successful sustainability and the challenges and lessons learned in achieving it. Audience participation will be encouraged. Tissues, gametes and isolated cells from humans, plants and animals may be preserved in a manner as to preserve viability and function. Retaining viability and function for a biospecimen presents specific challenges for biobankers. This session is designed to address unique challenges of preserving specific high-value biospecimens as well as overall challenges with workflow, quality assessment and downstream uses of specimens from living biobanks. Recent regulatory changes both in the USA and abroad contain requirements that may hinder data sharing and impede international research collaborations. Differences among the various regulations may cause conflicts in requirements for data handling once shared, due to the content and scope of the applicable regulations. As relating to human specimen research, the EU-General Data Protection Regulations recently implemented on May 25, 2018, has broad territorial reach outside of the EU and is significantly affecting multinational studies involving personal data from EU citizens or held by EU entities. While the regulations allow data sharing with countries such as the USA when there is appropriate legal basis, many of these approaches have considerable challenges. Furthermore, significant differences among the EU-GDPR, Common Rule and Health Insurance Portability and Accountability Act (HIPAA) are also creating implementation challenges for those wishing to share data internationally. The Nagoya Protocol contains requirements for movement of data and environmental and biological samples across international borders, as well as provisions for benefit back consideration for source locations of biological specimens. The implementation and the challenges to this regulatory framework will be presented. This session will provide an overview of these challenges and discuss attempts at resolutions. In addition, case studies in international collaborations will be discussed as well as proposed approaches to address the challenges in an interactive panel session. Digital pathology, along with digital radiology imaging systems is becoming the new norm within clinical digital imaging. They are an incredible resource for immediate review of disease status and tissue samples. The session will focus on digital imaging from radiology and pathology and its potential as a biobanking and research resource to catalogue disease, track the progression of disease and/or recovery, and use as a diagnostic tool. This session will also explore the innovative area of digital imaging as a learning tool to develop artificial intelligent (AI) systems and the potential use of AI systems to provide quality control, analysis of sample composition and computer assisted evaluation of disease. Originating from the ISBER 2018 Annual Meeting in Dallas, TX, we established a workgroup that has collected data from biorepository requests spanning institutions located in Australia, Canada, the UK and the US. We have also compiled data from different vendors and a variety of extraction kits. Our goal is to investigate the lack of standardization that exists between the blood collection and storage protocols at different institutions, the assays they intend to use, and the potential of compromising the health from willing research participants and donors.
We would like to have a discussion on the current data we have gathered with others in the biorepository field to see what their experiences are and if there is interest for more collaboration and contribution to this investigation. When receiving samples from clinical trials, external researchers, or other sources, a process of sample reconciliation must take place. This includes ensuring that all the samples that you were supposed to receive were received (and you didn't get any extra!), that you've received the associated sample metadata, and that this data can be associated with the samples that have been received. Though facilitated by sample tracking systems, the process of sample reconciliation can be a detailed and often tedious process. In the context of a clinical trial, it can also involve many external partners such as central laboratories, data management, clinical operations and CROs. This roundtable will discuss challenges that people have faced in reconciling samples and data and the solutions that have worked to make it an easier and more streamlined process.
BIOSAMPLES OPEN GOVERNANCE USING BLOCKCHAIN
LIVING BIOBANK SPECIAL INTEREST GROUP -GOALS AND DIRECTIONS
Facilitator: Jedidiah Lewis, Organ Preservation Alliance ISBER recently announced the launch of the new "Living Biobanking" special interest group. In this roundtable discussion, members of the ISBER community will discuss goals for the group and brainstorm future directions.
For more information visit: There are ongoing efforts to improve the human genome project to make it more representative of the world population as well as to make it as diverse as possible. Improvement in its diversity will ensure that genomic data is available for the use of people everywhere in the world. The importance of genomic data is immense, as it helps to predict disease occurrence as well as to guide the design of drugs for targeted therapy.
Unfortunately, Africa remains under-represented in the human genome project, due to the unavailability of African-centric genetic studies. This places Africans and all those of African descent at a disadvantage when it comes to access to personalized medicine. 54gene is a robust repository of biological specimens that will generate data to drive bespoke solutions to healthcare and patient management. In doing this, we are giving back to the communities that have contributed to the biobank, so everyone is a beneficiary of the initiative. The science of biobanking is being transformed by innovative new approaches to networked science. Networked biorepositories, which link data and biosamples across multiple sites, are often built with the intention of increasing the diversity of samples available for research as well as conducting studies with larger overall sample sizes. They also raise a number of novel challenges related to ethical, legal, and social issues (ELSI). In this presentation, Drs. Aaron Goldenberg and Kyle Brothers will discuss emerging ELSI that are raised by networked biorepositories, with a particular focus on different approaches taken by centralized biorepository networks and decentralized biorepository networks. The All of Us Research Program, the largest research effort ever undertaken by the NIH, will be discussed as a case study to demonstrate these points, with a particular focus on the way its centralized strategy has affected its missions to include diverse communities in research and to engage with underrepresented communities in its development and oversite. Genomic information on cancer is interesting. When it is tied to clinical outcome data, it is useful. But clinical outcomes are not purely driven by tumor characteristics, they are also driven by characteristics of the patient and the interaction of the patient and the tumor at the reference time that the tumor specimen was taken. A tumor sampled at the end of life and the same tumor sampled in stage 1 may have identical gene profiles, but the clinical outcome data will look very different to the person performing the survival analysis. This presentation will discuss new digital tools that can quantify health of the patient, making it possible for clinicians, biobanks, and drug developers to control for patient factors when analyzing outcome data. Both smartphone -based and in-clinic assessment tools will be discussed.
EVERY SPECIMEN HAS
DIRECT-TO-CONSUMER GENETIC TESTING: PROMISE, PITFALLS & PERILS
Ellen Matloff, MS, CGC, My Gene Counsel, LLC
It is estimated that 100 million people will have undergone direct-to-consumer (DTC) genetic testing by the year 2021. Many companies now offer these services, each with variable qualities, amounts, and types of data. How will that genetic data 26 PROGRAM REGIONAL MEETING NOVEMBER 3-5 be used -by consumers, companies, government, health care providers, big data aggregators, and pharma? The promise of genetic data, as well as the risks, will be discussed. We have established an ovarian cancer precision medicine initiative at the University of Minnesota. Our goal is to integrate genomic, clinical and functional data from patient samples to improve therapeutic options. Part of this initiative includes establishment of PDX mouse models for testing chemotherapy resistance. This presentation will describe our efforts to use PDX models in this initiative, including descriptions of the challenges this approach entails.
GENOME RESOURCE BANKING OF GENETICALLY MODIFIED RODENTS AND CURRENT CHALLENGES
Yuksel Agca, DVM, PhD, University of Missouri
There have been profound advances in the development of assisted reproductive technologies (ARTs; superovulation, in-vitro fertilization, micro-insemination, in-vitro embryo culture and transfer) during the past several decades. These ARTs in combination with novel genome editing methodologies (e.g. CRISPR / Cas9) have allowed creation of so many genetically modified (GM) animal models including mouse, rat, pig, non-human primates, drosophila and zebrafish to study genetics origins of human diseases and disorders. These animal models have made substantial contributions for the progression of biomedicine and human health. To this end, genome resource banking (GRB) is the systematic collection, cryo-storage, and re-distribution of cryopreserved germplasm (sperm, oocytes, and embryos) as well as embryonic and induced pluripotent stem cells from GM organisms in an organized, logistical, and secure manner. Currently, there is still an enormous need for efficient germplasm biotechnologies, novel cryopreservation protocols, 27 PROGRAM REGIONAL MEETING NOVEMBER 3-5 sensitive and reliable methods to screen cryopreserved germplasm. This would collectively ensure distribution high-quality, pathogen-free germplasm from these unique models of human diseases. In this presentation, emphasis will be given to current challenges regarding germplasm cryobanking of GM laboratory mouse and rats.
DEVELOPING AN OFF-THE-SHELF LIVING TISSUE SUPPLY Jedediah Lewis, JD, Organ Preservation Alliance
Recent advances in cryopreservation have created the prospect of providing a wide variety of living tissues off-the-shelf in the near future. ISBER has established a "Living Biobank" special interest group to explore applications for banking tumors, neural tissue, organ slices, and other biosamples for functional studies. This talk will provide context for this new area, tracing the arc of cryopreservation developments in related fields such as organ transplantation, tissue grafting, oncofertility, and tissue biomanufacturing and discussing how these advances could be applied to advance biobanking.
CRYOPRESERVATION OF CELLS AND SPORES BY ENCAPSULATION
Alptekin Aksan, PhD, University of Minnesota Cryopreservation of cells and spores requires cryoprotectant agents to be present extra-/intracellularly. Most cell membrane permeable cryoprotectant agents are cytotoxic (and even mutagenic), especially at room temperature. This creates significant challenges. The main mechanisms of damage the cryoprotectant agents protect biologicals against are associated with the kinetic and thermodynamic transitions of the extra-/intracellular aqueous milieu. In this presentation; we first describe the different mechanisms of damage induced during freeze/thaw and at cryogenic temperatures, and then introduce different methods (such as encapsulation in hydrogels) and processing practices that could be applied in order to minimize, and potentially eliminate, cytotoxic cryoprotectant use. The European Union General Data Protection Regulation (EU) 2016/679 (GDPR) seeks to harmonize data protection law in the EU. It clarifies the distinction between human biological samples and genetic data. Genetic data is explicitly considered a special category of personal data in the GDPR, subject to strict protection. However, not only protection, but also free movement of personal data within the EU is an objective of the GDPR.
SYMPOSIUM 4B: "ALL I REALLY WANT TO DO"… IS SHARE DATA WITH YOU: REGULATIONS FOR DATA SHARING AND INTERNATIONAL COLLABORATIONS
The key information on international collaboration and data sharing within and outside of the EU based on the GDPR will be presented. The EU does not consider countries such as the United States to offer an adequate level of data protection, thus the transatlantic data sharing possibilities are more limited than within the EU. Furthermore, the territorial scope of the GDPR is wide. It will in several instances apply to the processing of personal data of data subjects who are in the EU also where a controller or processor is outside the EU. Some keys to success to collaborate internationally when working with partners across sectors will be suggested.
IMPACT OF US PRIVACY LAW AND GDPR ON DATA SHARING FOR RESEARCH PURPOSES
David Peloquin, JD, Ropes & Gray LLP
This presentation will provide an overview of the challenges posed to research data sharing activities by privacy laws. Topics addressed will include HIPAA, US state law, and the European Union's General Data Protection Regulation. The speaker will address current areas of regulatory uncertainty and provide a summary of approaches taken to share data for research purposes while complying with privacy laws.
RAPIDLY EVOLVING CHALLENGES AND OPPORTUNITIES OF ACCESS AND BENEFIT SHARING (ABS) RULES FOR BIODIVERSITY COLLECTIONS AND RESEARCH
Scott Miller, PhD, Smithsonian Institution
The Nagoya Protocol on Access and Benefit Sharing (ABS) under the Convention on Biological Diversity, and its varied implementation by individual countries, has created confusion in the biodiversity research and collections community. The presentation will address what ABS includes and how it is implemented at national and international levels; how ABS is being addressed by other international bodies in agriculture, medicine, and other fields, such as the Commission on Genetic Resources in Food and Agriculture; current discussions about ABS and "digital sequence information"; and how biobanks can best respond to ABS and related issues.
SYMPOSIUM 5: FOREVER YOUNG? BIOSPECIMEN QUALITY TO ENSURE LONGEVITY
Great Northern
Tuesday, November 5 | 8:00am -9:30am
DEFINING QUALITY IN TISSUE BIOSPECIMENS
Stephen Hewitt, MD, PhD, National Cancer Institute
Historically, quality of tissue has been defined by subjective metrics based most commonly on histomorphology. Although histomorphology remains an essential metric of tissue quality, the quality of the individual bioanalytes -protein, RNA and DNA must be defined to ensure that the tissue is fit for purpose. As the preservation of tissue for biomedical research has a long history, closely tied to pathology practice, before the application of molecular biologic techniques, unwinding the preservation systems to define reproducible objective metrics of quality and subsequently dissect the process of preservation to determine what factors impact quality has been required. Although the 28 PROGRAM REGIONAL MEETING NOVEMBER 3-5 quality of all the metrics follows together, RNA is clearly the most sensitive metric for tissue quality. A "fit-for-purpose" approach to defining quality metrics and how they support research into tissue quality will be described.
WHAT IS THE ROLE OF PRE-ANALYTICAL VARIABLES ON THROMBOSIS BIOMARKERS IN A DIVERSE POPULATION OF CANCER PATIENTS?
Elizabeth Duffy, MA, Boston Medical Center
In a two and a half year study with 262 subjects, we aimed to examine the effect of three pre-analytic variables (PAVs) frequently encountered in hospital or research laboratories on thrombosis biomarkers in a racially diverse cancer population. Cancer is known to increase the risk of thromboembolism, but few biomarkers have been evaluated for PAVs in a cancer population. We focused our investigation to newly diagnosed, treatment naïve adult patients that were controlled for age, race and sex. All elements of the study were controlled by rigorous standard operating procedures (SOPs); including blood draw, blood processing, labeling, storage, testing, and analysis. PAVs studied were delay to processing, delay to testing and freeze-thaw cycles. This project underscores the importance of considering pre-analytic variables in blood processing, sample testing, storage, and assay quality control procedures during measurement of thrombosis and inflammation biomarkers.
DELTA-S-CYS-ALBUMIN: A LAB TEST THAT QUANTIFIES CUMULATIVE EXPOSURE OF ARCHIVED HUMAN BLOOD PLASMA AND SERUM SAMPLES TO THAWED CONDITIONS
Chad Borges, PhD, Arizona State University
Exposure of blood plasma/serum (P/S) to thawed conditions (> -30 °C) can produce biomolecular changes that skew measurements of biomarkers within archived patient samples, potentially rendering them unfit for molecular analysis. Since freeze-thaw histories are often poorly documented, objective methods for assessing molecular fitness prior to analysis are needed. This presentation will describe the development of a 10-µL, diluteand-shoot, intact-protein mass spectrometric assay of albumin proteoforms called "ΔS-Cys-Albumin" that serves as an endogenous marker of P/S exposure to thawed conditions based on the inexorable ex vivo S-cysteinylation (oxidizability) of albumin. In summary, average values of ΔS-Cys-Albumin in matched, fresh P/S samples from a population of non-acute cardiac patients were determined. The multi-reaction mechanism that drives changes in albumin S-cysteinylation is known and the rate law for it was established and accurately modeled in P/S-enabling back-calculation of the time at which unknown P/S specimens have been exposed to the equivalent of room temperature. Blind challenges and an unanticipated case study of samples collected under NIH sponsorship and intended for distribution by NIH ultimately demonstrated the functional utility of the ΔS-Cys-Albumin assay. Finding a cure for childhood cancers is a huge mission, especially in a limited resource country where research in this field is a challenge. There is not enough data available regarding how much LMICs contribute to research. There is great role of disparities in cancer etiology, treatment and response. Unavailability of quality specimens from these regions of the world has hindered inclusion of this specific racial/ethnic group in international population studies and other biomedical studies. This has led to their under-representation in different genomic projects such as HapMap, with the result that there is no available genomic data to detect biological differences and provide different treatment responses in this population.
SYMPOSIUM 6A: SHELTER FROM THE STORM: KEEPING BIOSPECIMENS ALIVE
There is a need for global efforts to increase in biomedical research aimed at developing personalized medicine. This in turn, will require a supply of high quality clinically annotated biospecimens fit-for-all research. Hence, having biorepositories established in different regions to standardize procedures supported by evidence-based science for all sample procurement, processing, storage, and distribution processes is a basic requirement.
We describe a general method, Conditional Reprogramming (CR), that rapidly expands both normal and malignant epithelial cells from diverse anatomic sites and mammalian species and does not require transfection with exogenous viral or cellular genes. Establishment of cell cultures from both normal and tumor tissue is highly efficient. Perhaps most important, cell cultures can be generated readily from core biopsies as well as cryopreserved human specimens. Normal breast and prostate cultures retain a normal karyotype and differentiation potential and cell lines derived from tumors retain their tumorigenic phenotype. We will describe several approaches that allow to enrich cancer cells from urine (for bladder cancer), blood (for prostate cancer),and pleural effusion (for non-small cell lung carcinoma). We also reported that these cancer cells from liquid biopsies were used to identify therapies for the patients. The ability to produce inexhaustible cell populations from small biopsies and cryopreserved specimens has the potential to transform biobanking repositories and current pathology practice by enabling genetic, biochemical, metabolomic, proteomic, and biological assays, including chemosensitivity testing as a functional diagnostics tool for precision cancer medicine. Automated whole slide imaging (WSI) scanners are now rendering diagnostic quality, high-resolution images of entire glass slides and combining these images with innovative digital pathology and artificial intelligence tools that are making it possible to integrate imaging into all aspects of pathology workflow including anatomical, clinical and molecular pathology. This is an especially exciting time in biobanking as these exciting tools and technology are rapidly becoming an integral component of the pathology practice, and will provide opportunities for innovations and advances in biobanking. This lecture will provide an overview of digital pathology and AI tools currently being used in the pathology workflow and to provide practical insights into the use of these technologies into transforming the workflow of a modern biobank. A framework of knowledge will be provided by an extended and interactive Q&A session which will serve to demystify the use of WSI and image analysis tools for biobanking applications, implementation challenges and pearls.
SYMPOSIUM 6B: INTEGRATING DIGITAL BIOSPECIMENS: DON'T LEAVE THEM "BLOWIN' IN THE WIND"
DIGITAL PATHOLOGY AND AI -FUTURE OPPORTUNITIES
Michael Feldman, MD, PhD, University of Pennsylvania Healthcare System
This presentation will focus on digital pathology and ML/AI tools that enable diagnostics and research. It will review elements of both as well as provide a vision of the future and how new workflows may be enabled in the digital pathology workspace. Future imaging technologies will also be introduced.
DIAGNOSTIC CONSENSUS THROUGH IMAGE SEARCH -LESSONS LEARNED FROM SEARCHING IN TCGA REPOSITORY OF WHOLE SLIDE IMAGES
Hamid Tizhoosh, PhD, Kimia Lab, University of Waterloo
Can we build diagnostic consensus using large repositories of histopathology images? The emergence of digital pathology has opened new horizons for histopathology and other related fields such as histology and cytology. Computer programs, most notably artificial-intelligence algorithms, can now operate on biopsy samples and assist pathologists during the diagnostic process. Whereas classification and segmentation methods have obvious benefits for some stages of this process, image search and retrieval may be a fundamental shift in diagnostic pathology by providing access to evidently diagnosed cases in existing repositories. This would offer ``virtual peer review'' to increase the accuracy and help to decrease the waiting time for diagnosis through computational consensus building. In this talk, some results for searching in the largest public repository (TCGA program) of digitized biopsy samples of almost 11,000 patients depicting different types of malignancies will be reported. Based on the anlaysis of findings, image search appears to be a reliable platform to exploit the archived (and so far unused) knowledge in digital repositories of histopathology images.
ESTABLISHING A SEARCHABLE IMAGING DATA COMMONS: MINING DIGITAL PATHOLOGY AND TUMOR IMAGING
David Gutman, MD, PhD, Emory University
Our team built the Cancer Digital Slide Archive, a web-based resource housing all 25,000+ digital pathology slides from the TCGA. Since then, we have developed the Digital Slide Archive (DSA), a flexible open-source slide management platform. We will highlight some of our ongoing work developing the DSA platform, including image analysis, visualization of machine-derived and human generated annotations, and analysis workflows.
The DSA is also being used to visualize data from the Human Tumor Atlas Network (HTAN), which is one of the NCI Moonshot projects. We will highlight some of our latest work demonstrating the visualization and analysis of new multiSpectral imaging technologies such as CODEX and cyCIF.
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Educational Workshop Summaries
PRE-CONFERENCE WORKSHOP: BIOBANKING 101
Zephyr Sunday, November 3 | 1:00pm -5:00pm *Pre-registration required. Registration fee of $95.
ISBER TOOLS -INTERNATIONAL REPOSITORY LOCATOR
Joanne Demchok, National Cancer Institute
The availability of a searchable (online) repository locator, is crucial to research infrastructure. To maximize the value of a specimen or collection, a researcher must be able to locate it. In addition, to generate data that contains statistical rigor, researchers may need to locate and access specimens from multiple repositories. An international repository locator (IRL), containing multiple repositories, would increase accessibility of repositories among key stakeholders including ISBER members, researchers, funding bodies, governments, and private industry.
The Working Group currently includes ISBER members from nine countries: Australia, France, Germany, Italy, the Netherlands, Qatar, Switzerland, the UK and the USA, with collective expertise in informatics, repository management, database management, and online locators.
HOW TO WRITE AN INFORMED CONSENT DOCUMENT
Helena Ellis, Biobanking Without Borders
All too often consent forms are written in language that is difficult to understand, with lots of legalese to fulfill regulatory requirements but without significant attention as to whether or not the form actually imparts key information to participants in an understandable manner. In the US the average person reads at the 7th or 8th grade level, so how can we make documents and the risks of genetic tests understandable? It takes an interest and time to review and revise the typical consent form, but the payoffs are substantial. There are many published guides and tools to help researchers write a comprehensible, reasonable length consent form, with simple words and conversational language. This workshop will provide easy to implement, step by step instructions to write clear biobanking consent forms based on published health literacy principles.
COLD CHAIN MANAGEMENT
Kathi Shea, Brooks Life Sciences
Time and temperature are two variables known to impact sample integrity. In this course we will focus on the approaches for managing the cold chain throughout the lifecycle of a sample. Various methods and tools that can be used for selection and qualification of shipping containers, work stations and storage units will be discussed, along with approaches that can be used for measuring and monitoring of temperature during sample acquisition, processing, handling, storage and distribution. Among the most significant changes related to biobanking in the revised Common Rule is a new provision for broad consent for the storage, maintenance, and research use of identifiable information and biospecimens for future research [45 CFR 46.116(d) ]. This broad consent allows participants to consent to future research on their biospecimens and associated data using a consent form that differs from the standard informed consent. The use of the broad consent allows secondary research using the biospecimens to meet an exemption that relies on a limited IRB review if certain conditions are met.
The new broad consent provision has a significant limitation. If a participant refuses to provide broad consent, an IRB can never subsequently waive informed consent for the use of the participant's biospecimens and associated data. This restriction requires significant tracking capability within an institution and, in some cases, even across institutions.
In this workshop, presenters and attendees will discuss the interpretation of this provision of the revised Common Rule, various strategies for implementing informed consent for future use of biospecimens under the revised Common Rule, and potential alternatives that exist under the revised Common Rule. Case examples will be used to illustrate various approaches that may be used under the Rule.
The format for the workshop will include several short introductory presentations, followed by an extensive, interactive discussion in which attendees will share their experiences and successful approaches to implement consent for future research on biospecimens and associated data under the revised Common Rule. 31 PROGRAM REGIONAL MEETING NOVEMBER 3-5 Perceived irreproducibility in research results using human tissue may be due to experimental design, exclusion of data, analytical approaches and statistics or may be secondary to bias associated with biospecimens including preanalytical variability, bioresource operations and biospecimens that are suboptimal. This workshop focuses on tissue variables that may impact research with human biospecimens. Problems can be exacerbated when new models such as reproducible biospecimens are developed or added to an existing bioresource. Irreproducibility increases if investigators and bioresource personnel are not adequately educated as to its causes. Personnel should be trained in new bioresource models before their adoption, e.g., living biobank.
Specific areas that will be addressed are the following:
• Pre-analytical variables that affect the usefulness of human tissues in research include: donor variables, changes secondary to initial diagnosis, warm and cold ischemia, tissue damage during surgery, limitations and errors imposed by collection, processing, storage and/or distribution of biospecimens, and variables of renewable biospecimens and their optimal use
• Quality assurance including quality control
• Sources of bias associated with the use of biospecimens in research including patient-derived renewable biospecimens
• Biospecimen features necessary to support research based on specific technologies and preparations that may require macro/microdissection
• Storage parameters and distribution approaches affecting biospecimens including renewable biospecimens
• Tissue utilization of biospecimens including renewable biospecimens
• Challenges in meeting future research needs Drs. McCall and Grizzle are experienced diagnostic and research pathologists with knowledge of bioresources, translational research, biorepository sciences and bioresource modifications needed for renewable biospecimens. A ten-minute discussion period will allow questions from participants and sharing of ideas. Biobanking standards and best practices are critical for ensuring that biospecimens are fit for purpose and that the results of studies using biospecimens from biobanks are meaningful and reproducible. Multiple standards and tools are available or under development, with a general goal of maximizing fitness-for-purpose of biological materials and associated data (BMAD). Included among these tools are standards falling under the umbrella of ISO 20387 general requirements for biobanks. ISBER also offers a number of tools, the most broad-ranging of which is the ISBER Best Practices (4th Edition + Addendum). Additionally, there are several other resources (e.g., CAP, CTRNet) available to facilitate other approaches to fitness-for-purpose in biobanks. How can biobanks use these best practices, tools and standards together to meet their individual goals and achieve fitness-for-purpose for their biobank?
WORKSHOP 3: IF IT'S FITNESS-FOR-PURPOSE YOU'RE CHASIN'… THE TOOLS, THEY ARE A CHANGIN': LEVERAGING STANDARDS, ISBER TOOLS AND OTHER RESOURCES
In this workshop, a mapping of the ISBER Best Practices 4th Edition against ISO 20387 will be presented. The differing goals of these and other tools will be examined, and paths of simultaneous implementation discussed in the context of multiple biobank scenarios/goals. Presenters will discuss how these tools can be used to meet specific requirements of ISO 20387 as well as the general pursuit of fitness-for-purpose. Among the tools to be introduced are the ISBER Self-Assessment Tool (SAT) and ISBER Self Auditing Tool.
A panel will discuss the application of this integrated map, with several case studies to demonstrate the considerations that come into play, and examine potential outcomes. The panel discussion will be followed by an audience question and answer session and interactive dialogue on the stand-alone and complementary application of standards, best practices, and other resources, including those apart from ISBER (e.g., CAP and CTR-Net) to achieve fitness-for-purpose through quality biobanking processes and products.
A significant number of biobanks may find that their pursuit of ISBER tools and other instruments will have taken them a significant distance towards implementation of the ISO 20387 standard. This workshop will build upon concepts described during previous ISBER workshops and will serve to help participants understand how biobanking standards, taken together with the broad spectrum of tools now available, can help to improve quality in biobanking. 32 PROGRAM REGIONAL MEETING NOVEMBER 3-5 Over the last decade recognition of the practice of biobanking has dramatically increased and in many academic centres biobanking has become routine. However, stakeholder engagement for biobanks is often limited and challenging. Many stakeholders in the biobanking process including patients, the general public, hospital administration, industry but also researchers and clinicians have no or little concept about the role and function of biobanks to advance research. This results in underuse and underfunding of biobanks. There is an obvious need to engage and educate stakeholders to increase the operational and financial viability of biobanks. However, many biobanks struggle with how and when to present the importance of biobanking to key players. An elevator pitch is a brief, persuasive speech that can be used to spark interest in a topic such as biobanking. We propose to develop elevator pitches for stakeholders in biobanking so that all biobankers have tools to persuade key stakeholders. Key stakeholders for which elevator pitches will be created include the public, patients, researchers, clinicians and nurses, administration of hospital or academic institution, industry, advocacy groups.
The objective of the workshop is to have attendees develop elevator pitches for a target audience to raise awareness and use of biobanks. This elevator pitch should contain key messages for the specific target group and should be no longer than 30 seconds.
Attendees of this workshop will be divided into working groups. Following a brief introduction to the purpose of the session, the groups will be given a target audience for which to develop a 30 second elevator pitch. The elevator pitch should describe key messages for the specific target group. Each working group will present their elevator pitch to the whole group with a discussion after each pitch.
All members will receive a written version of the elevator pitches presented at the workshop with permission of the presenters. 33 PROGRAM REGIONAL MEETING The increased acceptance and implementation of precision medicine, direct to consumer genomics and applications such as regenerative medicine have driven the need and adoption for the storage of primary samples and the isolation and storage of high quality, high molecular weight nucleic acid. One reason for primary sample and nucleic acid storage is the value of the information held within the sample.
The application of sequencing technologies to research and clinical settings has increased dramatically, generating vast amounts of data about variations in our genomes that could explain some differences in disease susceptibility, progression and how patients react to drugs. The move towards precision medicine and immune modulation therapy development, both requiring sequencing in the treatment workflow, drive the demand for faster processing, storage and data sample management techniques.
Efficient and effective storage ensuring sample integrity is of the utmost importance; retention of sample information with the associated phenotypic insight can provide a wealth of genetic and environmental information that can be unlocked in an attempt to better understand disease and health. In this workshop we explore industry collaborations to provide a solution to the increased need for efficient sample management and nucleic acid extraction that meet todays increased requirement for higher throughput full workflow solutions. 
Sponsors and Exhibitors
A2LA
Booth 14 A2LA is an internationally recognized accreditation body, whose primary mission is to provide comprehensive accreditation services for laboratories, inspection bodies, proficiency testing providers, reference materials producers and product certification bodies. Assessments are conducted using international standards and field specific technical requirements developed in cooperation with government and industry.
Abbott Informatics Booth 5
Abbott Informatics provides leading Laboratory Information Management Systems (LIMS) solutions that have served customers around the world for more than 30 years. The Abbott Informatics' STARLIMS solutions improve the reliability of laboratory sampling processes, support compliance with global regulatory requirements and industry standards, and provide comprehensive reporting, monitoring and analysis capabilities.
Agilent Technologies Booth 25
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent's expertise and trusted collaboration give them the highest confidence in our solutions.
Autoscribe Informatics Inc Booth 30
Whatever your Biobank Management needs, the Matrix Biobank Management System is easily adapted to suit them. Our simple to use graphical configuration tools set Matrix apart from other Biobank software solutions. Store and retrieve biospecimens while optimizing storage, managing data and tracking test results. Dual desktop and web applications provide maximum flexibility to work in the laboratory, across the internet, even offline. Please visit our booth to discover Matrix Biobank Management System.
Bahnson Environmental Specialties, LLC. Booth 16
Bahnson Environmental Specialties, an Emcor Company, is a leading manufacturer of high volume custom low temperature reach-in and walk-in freezers serving the pharmaceutical/biotech industry, contract biorepositories, and other critical product storage industries. For a complete review of our offerings of controlled environmental/stability rooms/chambers and services, visit our website.
Bluechiip Booth 18
Bluechiip offers a sample management suite of products for biobanks. Our system allows users to quickly register samples in batches and guide the user to the specific storage and retrieval location. The consumables have a Bluechiip wireless tag embedded inside that doesn't get affected by cryogenic temperatures, ice buildup and can even sense temperature at every scan. Therefore, the Bluechiip system solves issues like labels falling off or 2D barcodes not being able to read due to frost.
Brooks Life Sciences Booth 11 & 20
Brooks Life Sciences, a division of Brooks Automation, provides the life science industry with the most comprehensive portfolio of sample management solutions, enabling researchers worldwide to accelerate innovation and improve patient health. We offer automated storage, cryopreservation, informatics, sample storage, lab services, transportation, consumables and instruments. Technologies and services span the entire cold chain supporting research, GMP, pre/clinical, cell therapy, and biologics. 42 PROGRAM REGIONAL MEETING NOVEMBER 3-5
Bruker BioSpin Corp. Booth 22
Based on the complete standardization of NMR analysis of biospecimens, Bruker has developed a biobanking solution for QC of incoming samples for storage. A comprehensive number of quality parameters is delivered, from pre-analytics to degradation state or unreported drugs. NMR can deliver many metabolic information using the same spectra, which can be stored together with the metadata. Such standardized spectra are completely exchangeable between biobanks and research groups.
BSI Systems Booth 1 & 10
BSI Systems (BSI and BioShare) is a collection of specimen inventory and management products for your facility. BSI manages your biobank with validated software that tracks the complete life cycle of all specimens within your repository. BioShare is a platform for sharing specimens and/or datasets with others in the research community by providing a central location for researchers to search, submit requests, and track requester correspondence.
College of American Pathologists Booth 17
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation, including accreditation for biorepositories, and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the 2018 CAP Annual Report at CAP.ORG.
CORIS Life Sciences Monitoring, Inc. Booth 32
CORIS Life Sciences Monitoring provides remote 24/7 temperature monitoring of laboratory freezers at budget-friendly prices. Automated reporting, escalating and fully-customizable alerts, and artificial intelligence are just a few of our system's unique features. Our cloud-based platform does not require an on-site PC or server, and our patented technology does not require holes in firewalls--making it easy to get approval from your IT department. Contact us for a free quote.
Cryotherm Booth 2
For more than 50 years and with our own development, engineering and manufacturing departments, Cryotherm fulfills nearly every cryogenic need of our customers in the areas of life science, medicine, research and aerospace all over the world. For more information please visit us at www.cryotherm.de or www.cryotherminc.com.
At the ISBER Regional Meeting we would like to introduce our BIOSAFE ® LN2 freezer line with capacities from 2000 up to 123.000 [2ml tubes] together with our new BIOSAFE ® smart level control and monitoring unit. Whether as a stand-alone system, or together with our software packages BIOSAFE ® view and BIOSAFE ® iTrack, BIOSAFE ® LN2 freezer are providing all feature and options that a state of the art biorepository nowadays needs.
Ellab, Inc. Booth 23
